More than 10 years of complete remission of monoclonal gammopathy of undetermined significance and cessation of light chain deposition disease-associated nephrotic syndrome following treatment with vincristine, adriamycin and high-dose dexamethasone (VAD);Více než 10 let trvající kompletní remise monoklonální gamapatie nejistého významu a vymizení nefrotického syndromu vzniklého na podkladně light chain deposition disease po léčbě vinkristinem, adriamycinem a vysokými dávkami dexametazonu (VAD)

Vnitrni Lekarstvi

Volumn 56, Issue 3, 2010, Pages 240-246

  Adam, Zdeněk ^a   Nedbalkova M ^a   Krejci M ^a   Pour, L ^a   Husek K ^a   Vesely K ^b   Cermakova Z ^c   Krivanova A ^a   Mayer, J ^a   Hajek R ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^c Oddeleni Klinicke Biochemie   (Czech Republic)

Author keywords

AL amyloidosis; Light chain deposition disease; Monoclonal gammopathy of undetermined significance (MGUS); Multiple myeloma; Nephrotic syndrome; Renal insuficiency

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN KAPPA CHAIN; PARAPROTEIN; VINCRISTINE; IMMUNOGLOBULIN LIGHT CHAIN;

AMYLOIDOSIS; ARTICLE; BLOOD CELL COUNT; BONE MARROW BIOPSY; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE COURSE; DRUG MEGADOSE; FOLLOW UP; HEMATURIA; HUMAN; IMMUNOELECTROPHORESIS; KIDNEY BIOPSY; KIDNEY FUNCTION; LIGHT CHAIN; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE CYCLE TREATMENT; NEPHROTIC SYNDROME; OSTEOLYSIS; PLASMA CELL; PROTEINURIA; REMISSION; TREATMENT INDICATION; TREATMENT OUTCOME; TREATMENT RESPONSE; AGED; CASE REPORT; DRUG COMBINATION; IMMUNOLOGY; MALE;

AGED; DEXAMETHASONE; DOXORUBICIN; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE; NEPHROTIC SYNDROME; REMISSION INDUCTION; VINCRISTINE;

EID: 77951009302     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Randall RE, Williamson WC Jr, Mullinax F et al. Manifestation of systemic light chain deposition. Am J Med 1976; 60: 293-299.
2. Heilman RL, Velosa JA, Holley KE et al. Long term follow up and response to chemotherapy in patients with light chain deposition disease. Am J Kidney Dis 1992; 20: 34-41.
3. Pozzi C, Fogazzi GB, Banfi G et al. Renal disease and patient survival in light chain deposition disease. Clin Nephrol 1995; 43: 281-287.
4. Wohl P, Chadimová M, Englis M et al. Light chain deposition disease as a cause of renal failure. Čas Lék Čes 1998; 137: 721-724.
5. Zhu L, Herrera GA, Murphy-Ullrich JE et al. Pathogenesis of glomerulosclerosis in light chain deposition disease. Role for transforming growth factor-beta. Am J Pathol 1995; 147: 375-385.
6. Bedossa P, Fabre M, Paraf F et al. Light chain deposition disease with liver dysfunction. Hum Pathol 1988; 19: 1008-1014.
7. Girelli CM. Kappa light chain deposition of the liver. Eur J Gastroenterol Hepatol 1998; 10: 429-430.
8. Pelletier G, Fabre M, Attali P et al. Light chain deposition disease presenting with hepatomegaly: an association with amyloid-like fibrils. Postgrad Med J 1988; 64: 804-808. (Pubitemid 18260280)
9. Kijner CH, Yousem SA. Systemic light chain deposition disease presenting as multiple pulmonary nodules. A case report and review of the literature. Am J Surg Pathol 1988; 12: 405-413.
10. Bhargava P, Rushin JM, Rusnock EJ et al. Pulmonary light chain deposition disease. Report of five cases and review of literature. Am J Surg Pathol 2007; 31: 267-276. (Pubitemid 46175028)
11. Samanez C, Domingo A, Ciberia MT. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma. Eur J Haematol 2006; 76: 83-85.
12. Lambotte O, Dürrbach A, Ammor M et al. Association of a POEMS syndrome and light chain deposit disease: first case report. Clin Nephrol 2001; 55: 482-486. (Pubitemid 32499504)
13. Merta M, Rysavá R, Zabka J et al. Kidney involvement in light-chain deposition disease. Sb Lek 2002; 103: 397-403.
14. Lin J, Markowitz GS, Valeri AM et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482-1492. (Pubitemid 32666331)
15. Preud'homme JL, Aucouturier P, Touchard G et al. Monoclonal immunoglobulin deposition disease (Randall type). Relationship with structural abnormalities of immunoglobulin chains. Kidney Int 1994; 46: 965-972.
16. Venkataseshan VS, Faraggiana T, Hughson MD et al. Morphologic variants of light-chain deposition disease in the kidney. Am J Nephrol 1988; 8: 272-279.
17. Salant DJ, Sanchorawala V, D'Agati VD. A case of atypical light chain deposition disease - diagnosis and treatment. Clin J Am Soc Nephrol 2007; 2: 858-867.
18. Baur A, Stäbler A, Lamerz R et al. Light chain deposition disease in multiple myeloma: MR imaging features correlated with histopathological findings. Skeletal Radiol 1998; 27: 173-176. (Pubitemid 28181765)
19. Ferrario F, Rastaldi MP. Histopathological atlas of renal diseases: light chain deposition disease. J Nephrol 2005; 18: 499-502.
20. Gokden N, Barlogie B, Liapis H. Morphologic heterogeneity of renal light-chain deposition disease. Ultrastruct Pathol 2008; 32: 17-24. (Pubitemid 351323398)
21. Joh K. Pathology of glomerular deposition diseases. Pathol Int 2007; 57: 551-565. (Pubitemid 47222704)
22. Gu X, Herrera AG. Light chain mediated acute tubular interstitial nephritis: a poorly recognized pattern of renal disease in patients with plasma cell dyscrasia. Arch Pathol Lab Med 2006; 130: 165-169. (Pubitemid 43237983)
23. Hofmann-Guilaine C, Nochy D, Jacquot C et al. Association light chain deposition disease (LCDD) and amyloidosis. One case. Pathol Res Pract 1985; 180: 214-219.
24. Jacquot C, Saint-Andre JP, Touchard G et al. Association of systemic light-chain deposition disease and amyloidosis: a report of three patients with renal involvement. Clin Nephrol 1985; 24: 93-98. (Pubitemid 15023014)
25. Okura T, Miyoshi K, Nagao T et al. Light chain deposition disease developing 15 years following the diagnosis of monoclonal gammopathy of undetermined significance. Intern Med 2009; 48: 101-104.
26. Pozzi C, D'Amico M, Fogazzi GB et al. Light chain deposition disease with renal involvement: clinical characteristics and prognostic factor. Am J Kidney Dis 2003; 42: 1154-1163. (Pubitemid 37486758)
27. Barraclough KA, Dowling JP, Schwarer AP et al. Sequential autologous peripheral blood stem cell transplantation and kidney transplantation of light chain deposition disease. Nephrol Dial Transplant 2007; 22: 1268-1269.
28. Firkin F, Hill PA, Dwyer K et al. Reversal of dialysis dependent renal failure in light chain deposition disease by autologous peripheral blood stem cell transplantation. Am J Kidney Dis 2004; 44: 551-555. (Pubitemid 39164631)
29. Hassoun H, Flombaum C, D'Agati VD et al. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease. Bone Marrow Transplant 2008; 42: 405-412.
30. Pineda-Roman M, Tricot G. High-dose therapy in patients with plasma cell dyspasias and renal dysfunction. Contrib Nephrol 2007; 153: 182-194. (Pubitemid 44836021)
31. Royer B, Arnulf B, Martinez F et al. High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int 2004; 65: 642-648. (Pubitemid 38130660)
32. Sakakima M, Fujigaki Y, Tsuji T et al. High dose chemotherapy and stem cell support in a patient of light- and heavy-chain deposition disease with abnormal marrow cell surface antigens and no monoclonal protein. Intern Med 2005; 44: 970-974. (Pubitemid 41644098)
33. Wahner-Roedler DL, Kyle R. Heavy chain disease. Best Pract Res Clin Haematol 2005; 18: 729-746.
34. Leung N, Lager DJ, Gertz MA et al. Long-term outcome of renal transplantation in light-chain deposition disease. Am J Kidney Dis 2004; 43: 147-153. (Pubitemid 38049446)
35. Leung N, Slezak JM, Bergstralh EJ. Acute renal insufficiency after high dose melphalan in patients with primary systemic amyloidosis during stem cell transplantation. Am J Kidney Dis 2005; 45:102-111. (Pubitemid 40038050)
36. Ganeval D, Noël LH, Preud'homme JL et al. Light chain deposition disease: Its relation with AL type amyloidosis. Kidney Int 1984; 26: 1-9.
37. Gertz MA, Lacy MQ, Lust JA et al. Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis. Med Oncol 1999; 16: 104-109.
38. Dhodapar MV, Hussein MA, Rasmussen E et al. Clinical efficacy of high dose dexamethasone wit maintenance dexamethasone/interferon alpha in patients with primary systemic amyloidosis. Blood 2004; 104: 3520-3526.
39. Palladini G, Perfetti V, Obici L et al. Association of melphalan and high dose dexamethasone is effective and well tolerated in patients with AL-amyloidosis, who are ineligible for stem cell transplantation. Blood 2004; 103: 2936-2938. (Pubitemid 38451663)
40. Palladini G, Russso P, Nuvolone M et al. Treatment with oral melphalan plus dexamethasone produces long term remission in AL-amyloidosis. Blood 2007; 110: 787-788.
41. Jaccard A, Moreau P, Leblond V et al. Autologous stem cell transplantation versus oral melphalan and high dose dexametasone in patients with primary AL-amyloidos. Randomized trial. Blood 2005; 106: 421.
42. Gerz MA, Lacy MQ, Lust JA et al. Phase Il trial of high dose dexamethasone for previously treated immunoglobulin light-chain amyloidosis. Am J Hematol 1999; 61: 115-119.
43. Röcken C, Ernst J, Hund E et al. Interdisciplinary guidelines on the diagnosis of and therapy for systemic amyloidosis. Dtsch Med Wochenschr 2006; 131 (27 Suppl 2): S45-S66.
44. Comezo RL. Managing systemic light chain amyloidosis. J Natl Compr Canc Netw 2007; 5: 179-187.
45. Lorenz EC, Gertz MA, Fervenza FC et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transplant 2008; 23: 2052-2057.
46. Palladini G, Perfetti V, Merlini G. Therapy and management of systemic AL-amyloidosis. Swiss Med Wkly 2006; 136: 715-720. (Pubitemid 46032193)
47. Brockhurst I, Harris KP, Chapman CS. Diagnosis and monitoring a case of light-chain deposition disease in the kidney using a new, sensitive immunoassay. Nephrol Dial Transplant 2005; 20: 1251-1253. (Pubitemid 40862121)
48. Šěudla V, Minařík J, Schneiderka P et al. Význam séroých hladin volných lehḱch fetëzcû imunoglobulinu vdiagnostice a hod-noceni aktivity mnohoičtného myelomu a vybraných monoklonální ch gamapatif́. Vnitř Léík 2005; 51: 1249-1259.
49. Tichý M, Hrnčíř Z, Urban P et al. Monoklonální imunoglobuliny. Klin Biochem Metabol 2004; 12: 84-87.
50. Doubek M, Brychtova Y.Tomiska M et al. Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera. Acta Haematol 2005; 113:150-151. (Pubitemid 40522821)
51. Tichý M, Urban P, Matěja P et al. Laboratorní analýza souboru 3049 monoklonálních imunoglobulinu̇. Klin Biochem Me-tabol 2002; 10: 257-261.
52. Tichý M. Laboratorní analýza monokloná lních imunoglobulinů (paraproteinů). Český Těšín: Finidr 1997.